• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Refractory Multiple Myeloma - Pipeline Review, H2 2012 Product Image

Refractory Multiple Myeloma - Pipeline Review, H2 2012

  • Published: July 2012
  • 147 pages
  • Global Markets Direct

Refractory Multiple Myeloma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Refractory Multiple Myeloma - Pipeline Review, H2 2012', provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma. 'Refractory Multiple Myeloma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Refractory Multiple Myeloma.
- A review of the Refractory Multiple READ MORE >

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Refractory Multiple Myeloma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Refractory Multiple Myeloma 12
Refractory Multiple Myeloma Therapeutics under Development by Companies 14
Refractory Multiple Myeloma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Refractory Multiple Myeloma Therapeutics – Products under Development by Companies 21
Refractory Multiple Myeloma Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Refractory Multiple Myeloma Therapeutics Development 23
Bristol-Myers Squibb Company 23
Abbott Laboratories 24
Eli Lilly and Company 25
Merck & Co., Inc. 26
Piramal Healthcare Limited 27
Millennium Pharmaceuticals, Inc. 28
Cephalon, Inc. 29
ImmunoGen, Inc. 30
Pfizer Inc. 31
Celgene Corporation 32
Onyx Pharmaceuticals, Inc. 33
EntreMed, Inc. 34
AEterna Zentaris Inc. 35
Array BioPharma Inc. 36
Threshold Pharmaceuticals, Inc. 37
Acetylon Pharmaceuticals, Inc. 38
Refractory Multiple Myeloma – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 46
ENMD-2076 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-833923 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Kyprolis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Kyprolis - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TH-302 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BMS-936564 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
P276 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Aflibercept - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Zolinza + Revlimid + Dexamethasone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PD 0332991 + Velcade + Dexamethasone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
Dasatinib + Velcade + Dexamethasone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 64
Sprycel + Revlimid + Dexamethasone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 66
Treanda + Velcade - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Perifosine + Dexamethasone - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Revlimid - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Actimid + Dexamethasone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Actimid - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Perifosine + Lenalidomide + Dexamethasone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Velcade + Tipifarnib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Dexamethasone + CC-4047 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
IMGN901 + Revlimid + Dexamethasone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Bevacizumab + Bortezomib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Decadron + Biaxin + CC-4047 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Bendamustine + CC-5013 + Dexamethasone + Aspirin + H-2 blocker + Diflucan - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 82
Gemcitabine + Busulfan + Melphalan + Dexamethasone + Palifermin + Stem Cell Transplantation - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 86
R&D Progress 87
Cisplatin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CC 4047 + Bortezomib + Dexamethasone - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MLN9708 + Lenalidomide + Dexamethasone - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ARRY-520 + Bortezomib + Dexamethasone - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ACY-1215 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Carfilzomib + Lenalidomide + Vorinostat + Dexamethasone - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ACY-1215 + Bortezomib + Dexamethasone - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
TH-302 + Bortezomib - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
CEP-18770 + Lenalidomide + Dexamethasone - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Amrubicin + Lenalidomide + Dexamethasone + Aspirin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
BMS-936564 + Revlimid + Dexamethasone - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
BMS-936564 + Velcade + Dexamethasone - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
LY2127399 + Bortezomib - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
ARRY-520 + Bortezomib + G-CSF - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 109
Elotuzumab + Bortezomib + Dexamethasone - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Pomalidomide + Bortezomib + Dexamethasone - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Fludarabine Phosphate + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil + Allogeneic Hematopoietic Stem Cell Transplantation + Yttrium Y 90 Anti-cd45 Monoclonal Antibody Bc8 + Total-Body Irradiation - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 115
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates 116
Refractory Multiple Myeloma Therapeutics – Discontinued Products 140
Refractory Multiple Myeloma Therapeutics - Dormant Products 141
Refractory Multiple Myeloma – Product Development Milestones 142
Featured News & Press Releases 142
Jul 02, 2012: Onyx Pharma Initiates Phase III Kyprolis Head-To-Head Comparison Trial Versus Velcade In Patients With Relapsed Multiple Myeloma 142
Jun 28, 2012: Millennium Initiates Phase III Trial Of MLN9708 In Patients With Relapsed And/Or Refractory Multiple Myeloma 143
Jun 21, 2012: Celgene's NDA For Pomalidomide And Dexamethasone Combination Therapy Accepted For Standard Review By FDA 143
Jun 05, 2012: Aeterna Zentaris Announces Publication Of Phase I Data For Perifosine In Multiple Myeloma In British Journal Of Hematology 144
Apr 26, 2012: Onyx Pharma Announces FDA Advisory Committee To Review Carfilzomib For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma 144
Jun 07, 2011: Onyx Pharma Announces Data Presentations On Carfilzomib At 16th Congress Of European Hematology Association 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Tables
Number of Products Under Development for Refractory Multiple Myeloma, H2 2012 12
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Bristol-Myers Squibb Company, H2 2012 23
Abbott Laboratories, H2 2012 24
Eli Lilly and Company, H2 2012 25
Merck & Co., Inc., H2 2012 26
Piramal Healthcare Limited, H2 2012 27
Millennium Pharmaceuticals, Inc., H2 2012 28
Cephalon, Inc., H2 2012 29
ImmunoGen, Inc., H2 2012 30
Pfizer Inc., H2 2012 31
Celgene Corporation, H2 2012 32
Onyx Pharmaceuticals, Inc., H2 2012 33
EntreMed, Inc., H2 2012 34
AEterna Zentaris Inc., H2 2012 35
Array BioPharma Inc., H2 2012 36
Threshold Pharmaceuticals, Inc., H2 2012 37
Acetylon Pharmaceuticals, Inc., H2 2012 38
Assessment by Monotherapy Products, H2 2012 39
Assessment by Combination Products, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 45
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates 116
Refractory Multiple Myeloma Therapeutics – Discontinued Products 140
Refractory Multiple Myeloma Therapeutics – Dormant Products 141

List of Figures
Number of Products under Development for Refractory Multiple Myeloma, H2 2012 12
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 39
Assessment by Combination Products, H2 2012 40
Assessment by Route of Administration, H2 2012 41
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Molecule Type, H2 2012 43
Assessment by Stage and Molecule Type, H2 2012 44

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos